Skip to main content
. 2021 Nov-Dec;66(6):616–619. doi: 10.4103/ijd.ijd_71_21

Table 2.

Comparison between our study and NACDG study*

Our study NACDG study*
Number of patients (sample size) 2138 5594
Prevalence of 2+/3+ammonium persulfate reactions 2.7% 0.75%
Patients with definite and probable clinical relevance of ammonium persulfate allergy 3/61 (21%) 26/97 (26.8%)

*North American Contact Dermatitis Group Patch Test Results: 2015-2016[8]